Valuation: Synovics Pharmaceuticals, Inc.

Market Cap 16.41L 14.19L 13.25L 12.16L 22.86L 16Cr 23.23L 1.55Cr 61.02L 7.83Cr 61.6L 60.26L 26Cr P/E 2007
-0.73x
P/E 2008 -2.06x
Enterprise Value 81.29L 70.31L 65.66L 60.24L 1.13Cr 77Cr 1.15Cr 7.7Cr 3.02Cr 39Cr 3.05Cr 2.99Cr 128.19Cr EV / Sales 2007
1.81x
EV / Sales 2008 0.6x
Free-Float
95.75%
Yield 2007 *
-
Yield 2008 -
Change 5-day change 1-year change 3-year change Capi.($)
-99.50%-.--% - - 3.65T
-0.52%+3.21%+85.02%+161.12% 1,05700Cr
+0.88%+1.13%+51.13%+49.76% 62TCr
+0.89%-1.95%+23.73%+63.67% 43TCr
+0.71%+3.87%+47.45%+38.68% 36TCr
+0.64%-0.49%+35.39%+40.21% 30TCr
+0.39%-5.83%+8.64%+9.28% 25TCr
+1.51%+6.69%+44.34%+62.47% 22TCr
+3.92%-0.46%-1.21%-44.09% 21TCr
+1.80%+2.30%+20.79%+65.13% 17TCr
Average -8.77%+0.87%+35.03%+49.58% 40.23TCr
Weighted average by Cap. +1.12%+1.22%+48.34%+75.33%

Financials

2007 2008
Net sales 2.35Cr 2.03Cr 1.9Cr 1.74Cr 3.27Cr 223.33Cr 3.32Cr 22Cr 8.73Cr 111.94Cr 8.81Cr 8.62Cr 370.07Cr 2.6Cr 2.25Cr 2.1Cr 1.92Cr 3.62Cr 247.06Cr 3.68Cr 25Cr 9.66Cr 123.83Cr 9.75Cr 9.53Cr 409.39Cr
Net income -2.09Cr -1.8Cr -1.68Cr -1.55Cr -2.91Cr -198.51Cr -2.95Cr -20Cr -7.76Cr -99Cr -7.83Cr -7.66Cr -328.93Cr -40.06L -34.65L -32.36L -29.68L -55.83L -38Cr -56.72L -3.8Cr -1.49Cr -19Cr -1.5Cr -1.47Cr -63Cr
Net Debt 1.88Cr 1.63Cr 1.52Cr 1.39Cr 2.62Cr 178.83Cr 2.66Cr 18Cr 6.99Cr 90Cr 7.06Cr 6.9Cr 296.32Cr 64.88L 56.12L 52.41L 48.08L 90.43L 62Cr 91.87L 6.15Cr 2.41Cr 31Cr 2.44Cr 2.38Cr 102.32Cr
Logo Synovics Pharmaceuticals, Inc.
Synovics Pharmaceuticals, Inc. (Synovics) is a specialty pharmaceutical company engaged in the development, manufacturing and commercialization of generic over the counter (OTC) pharmaceutical products and generic prescription drug products. The Company is a manufacturer, packager and distributor of private label, or store brand, OTC products to chain drug stores, wholesalers and distributors throughout the United States. The Company’s OTC product categories include analgesics, cough and cold, antihistamines, asthma relief and laxatives. The Company has two primary subsidiaries, Kirk Pharmaceuticals, LLC (Kirk), and ANDAPharm, LLC (ANDAPharm). Kirk manufactures and distributes OTC products developed by or licensed to the Company. ANDAPharm serves as the product research and RX manufacturing arm of the Company with a focus on the development of active compounds for drugs.
Employees
-